Shanghai Labway Clinical Laboratory (301060.SZ) shareholder Hailan Group plans to reduce its shareholding by no more than 2%.

Announcement from Shanghai Labway Clinical Laboratory (301060.SZ): The company's shareholder, Hailan Group Limited (referred to as "Hailan Group"), plans to reduce its holdings of the company's shares by no more than 7.9704 million shares (representing 2.00% of the total share capital excluding shares held in the company's repurchase special account) through centralized bidding and/or block trading within 3 months after 15 trading days from the disclosure of this reduction plan.